# Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

> **NCT05380063** · PHASE4 · COMPLETED · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 2300 (actual)

## Conditions studied

- Coronary Artery Disease
- Coronary Artery Bypass Grafting
- Dual Antiplatelet Therapy
- Bleeding
- Myocardial Infarction
- Myocardial Ischemia
- Angina Pectoris

## Interventions

- **DRUG:** De-escalated Dual Antiplatelet Therapy
- **DRUG:** Dual Antiplatelet Therapy

## Key facts

- **NCT ID:** NCT05380063
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-14
- **Primary completion:** 2025-07-08
- **Final completion:** 2025-07-10
- **Target enrollment:** 2300 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05380063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05380063, "Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05380063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*